All In Biotech

Drug Trial Radar · NCT02554773

An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B

An Open-label Extension Study of Subcutaneously Administered Fitusiran in Patients With Moderate or Severe Hemophilia A or B Who Have Participated in a Previous Clinical Study With Fitusiran

Last checked: Nov 19, 2026Latest source record: Jun 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

34

Actual

Start

Sep 18, 2015

Primary completion

Mar 21, 2023

Study completion Mar 21, 2023

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Sep 18, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To evaluate the long-term safety and tolerability of fitusiran in male patients with moderate or severe hemophilia A or B Secondary Objectives: * To investigate the long-term efficacy of fitusiran * To characterize the safety and efficacy of concomitantly administered Factor VIII (FVIII), Factor IX (FIX) or bypassing agents (BPA) and fitusiran for treatment of bleeding episodes * To assess changes in health-related quality of life (QOL) over time * To characterize antithrombin (AT) reduction and thrombin generation (TG) increase * To characterize the pharmacokinetics (PK) of fitusiran

Conditions

  • Hemophilia A
  • Hemophilia B

Interventions

  • Fitusiran (SAR439774)Drug

    Pharmaceutical form: solution for injection Route of administration : subcutaneous (sc)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs)Time frame: From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
  2. Number of Participants With Potentially Clinically Significant Abnormality (PCSA): HematologyTime frame: From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
  3. Number of Participants With Potentially Clinically Significant Abnormality: Clinical ChemistryTime frame: From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
  4. Number of Participants With Potentially Clinically Significant Abnormality: UrinalysisTime frame: From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
  5. Number of Participants With Potentially Clinically Significant Abnormality: Vital SignsTime frame: From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
  6. Number of Participants With Potentially Clinically Significant Abnormality: Electrocardiogram (ECG)Time frame: From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
  7. Number of Participants With Potentially Clinically Significant Abnormality: Physical ExaminationTime frame: From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)

Locations

12 sites in 5 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Ann Arbor, Michigan

  • Clinical Trial Site

    Pittsburgh, Pennsylvania

  • Clinical Trial Site

    Plovdiv, Bulgaria

  • Clinical Trial Site

    Sofia, Bulgaria

  • Clinical Trial Site

    Kirov, Russia

  • Clinical Trial Site

    Moscow, Russia

  • Clinical Trial Site

    Zurich, Switzerland

  • Clinical Trial Site

    Basingstoke, United Kingdom

  • Clinical Trial Site

    Glasgow, United Kingdom

  • Clinical Trial Site

    London, United Kingdom

  • Clinical Trial Site

    London, United Kingdom

  • Clinical Trial Site

    Truro, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.